Brief: Lantern Pharma Reports First Quarter 2023 Financial Results
09/05/2023 21:22
May 9 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS AND
OPERATIONAL HIGHLIGHTS
* LANTERN PHARMA INC - $51.5 MILLION IN CASH, CASH
EQUIVALENTS,
AND MARKETABLE SECURITIES AS OF MARCH 31, 2023
* LANTERN PHARMA INC - HAS A CASH RUNWAY INTO 2025
* LANTERN PHARMA INC - QTRLY LOSS PER SHARE $0.36
Source text for Eikon: ID:nBw85LQ1ga
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview